Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet.
Source link
Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients
